Here are my notes from Q2FY17 concall. I have organized the info from different questions
India-
Rev grew 12% vs Q1 growth of 3%. Price growth in Q2 was 6%, volume growth 1%, new products 2%.
Launched a CNS product (Lurasidone) for strengthening position in anti psychotic market.
Focus continues on specialty and productivity. Per capita productivity increased to 6 lakhs. Focus only on prescriptions. Specialists take some time to start recco our products. De focusing on anti-infectives.
Going fwd the growth will be better than the market growth.
Brazil-
20% rev growth in INR,
Local currency growth was 31% in Q1 and 8% in Q2
Launched first branded generic of Olmisartan- 75mn Brazilian Real
Trazidone- 110mn. Launch before end Q2
Tender business declined heavily (20%) due cut in govt spend.
Had problem in QC lab which caused inventory pile up in trade business.
USA
On Abilify, 4 additional competitors impacted pricing. It has now become a normal product, on par with any other product in our portfolio.
Esomeprazole/Nexium also price pressure. Auro came in April only
There was one product where we saw irrational competition.
Dont expect any large impact on any products going fwd. Hangover phase is over and now business is usual. there will not be a repeat of drop from Q1 to Q2.
Impact of pricing pressure and volume is across the board, not just Nexium and Abilify. Lost some contracts. Exited where prices are not good. US revenue going fwd- environment is changing. Firstly, USFDA is close to its GDUFA commitment. Secondly, Walmart + McKesson joint purchases (merger) started from 1st April. Thought at beginning of the year that Pricing impact will be 5-10% on the base business vs 3-5% in normal year.
The changing environment also impacts the price they are willing to pay for acquisitions.
We have 56 approved products- Some we are out of market and in some we are increasing capacities, so there is a scope of growth even without additional approvals. eg. Detrol LA- we could not increase market share because of capacity constraints. going fwd we will increase capacity on that product. Another example-venlafaxine was not produced much because other products were prioritized. The market for this is growing 7-8% in unit terms. Such products will get revived.
Guided 10 launches but didnt launch anything this year. Out of 3 approvals this year, we will launch 2 in Nov and 1 in Jan. Hoping some more approvals by end of fiscal year…one additional approval by end Oct. Rest is in hands of USFDA.
4 sure shot launches for FY17. Rest 6 approvals were expected but havent come yet. At least 2-3 should come this year. We can end the year with 6-7 launches
One launch will be Floxetine hydrochloride (prozac??) November launch, already approved. Small pdt which sells through whole saler channel. 85% share of Mylan, 10-15% Teva. Dont expect more players.
Renevela/Sevelamer - responded to all questions. Waiting for USFDA to come back on that.
Quetiapine/Seroquel (it had 2013 annual sales of 1.3bn)- We have a pending query which we are wworking on. We can be on wave 1 or wave 2 of launch.
R&D
Currently 20 filings under review and 6 tentative approvals
Filed 6 ANDA in H1 including 1st derma ANDA, 1 FTF, 1 in-licensed pdt for which regulatory work was done at Torrent but development was done outside.
Target of 4-5 filing per Q. FY17 total will be 15+
15 launches a year from FY18-19 onwards
Areas- Derma, Onco, Opthal.
111cr spent in Q2 up from 57cr last year.
Dahej
8 pdts approved
Ramping up production from Dahej
Approval rate is slightly slower than expected, so the utilization is low. However full costs are getting charged to P&L.
Glochem was acquired for 120cr, small acquisition. It was already making APIs for Torrent. We will file more DMFs from here- targeting 8-10 per year. We have now 3 API plants- 60+60+50 tonnes. 40% API are made in-house currently.
Why are we carrying debt when we have current investments, cash? Large part is in overseas subsidiary. Want to have some liquidity to care of capex. Net-net basis we have very low debt. Looking for some refinancing to reduce interest cost.
Tax rate 17% in H1. Full year can be 18-20%
Capex guidance- 500cr per year for next 3 years
Acquisitions
First prio for inorganic growth is India but all available acquisitions are very expensive. 2nd Brazil and US. 3rd UK. Want to expand scope by therapeutic areas/dosage form rather than scale.
USD 400-500mn would be a comfortable size. More than that we will have to look for higher borrowing